Objectives: Palivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. While palivizumab is more effective if used correctly, compliance with the monthly dosing is suboptimal. We established a pharmacist-managed RSV prevention clinic in an effort to improve compliance. The primary objective of this study was to determine the impact of a pharmacist-managed RSV prevention clinic on palivizumab compliance.
Methods: A chart review was performed. Patients who received palivizumab between September 2009 and April 2012 were identified. Compliance was determined as the number of patients who received eligible doses at 28- to 30-day intervals, consecutively.
Results: One hundred seventy-two patients received at least 1 dose of palivizumab. An average of 92% of patients who received at least 1 dose subsequently received all doses of palivizumab during the RSV season. Of those, 88% received all eligible doses in consecutive 28-to 30-day intervals.
Conclusion: A pharmacist-managed RSV prevention clinic can assist physicians in the prevention of RSV by increasing compliance with palivizumab dosing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640300 | PMC |
| http://dx.doi.org/10.5863/1551-6776-22.5.338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic.
J Pediatr Pharmacol Ther
January 2017
Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee.
Objectives: Palivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. While palivizumab is more effective if used correctly, compliance with the monthly dosing is suboptimal. We established a pharmacist-managed RSV prevention clinic in an effort to improve compliance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!